Alzheimer's Disease Biomarkers: More Than Molecular Diagnostics
Article first published online: 6 MAR 2013
© 2013 Wiley Periodicals, Inc.
Drug Development Research
Special Issue: Biomarkers in Drug Development and Companion Diagnostics
Volume 74, Issue 2, pages 92–111, March 2013
How to Cite
Anderson, D. C. (2013), Alzheimer's Disease Biomarkers: More Than Molecular Diagnostics. Drug Dev. Res., 74: 92–111. doi: 10.1002/ddr.21073
- Issue published online: 19 MAR 2013
- Article first published online: 6 MAR 2013
- SRI International
- Alzheimer's disease;
Alzheimer's disease (AD) is a complex, progressive, and eventually fatal neurodegenerative disease that currently lacks effective treatment options. The disease process is only partially understood. Biomarker identification and analysis will be important for facilitating a deeper understanding of the molecular nature of the disease process and neuropathology, diagnosis of the disease at its earliest stages, in assessing disease progression and to enable the drug discovery and development process. This review assesses progress in a number of areas of AD biomarker discovery and development, constituting a potential systems approach to understanding and diagnosing this disease, including next-generation DNA sequencing of human genomes, genome-wide association studies, epigenetics (including DNA methylation and micro-RNA profiling), gene expression profiling, lipidomics and metabolomics, proteomics, and neuroimaging.